The U.S. Food and Drug Administration has cleared EchoGo Pro, an artificial intelligence (AI) decision support software application from U.K. software developer Ultromics for identifying coronary artery disease on echocardiograms.
EchoGo Pro flags indications of coronary artery disease and sends a report to the ordering physician. The software was developed with large echocardiography datasets from the University of Oxford.
Ultromics plans to offer it as a stress-echo module in its cloud-based EchoGo suite, along with EchoGo Core, software for systolic function and strain analysis, it said.
